Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Data on the Clinical Activity of Simeprevir in Combination With AL-335 and Odalasvir (JNJ-4178) Presented at the 2017 Liver Meetingtm


STOCKHOLM, Oct. 23, 2017 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)today communicates phase IIb data on JNJ-4178, the triple combination consisting of simeprevir, odalasvir and AL-335, following presentations at the 2017 Liver Meetingtm organized by the American Association for the Study Liver Diseases (AASLD) and held in Washington DC on 20-24 October.

SVR12 data from OMEGA-1, a global open-label phase IIb study of the efficacy and safety of JNJ-4178 in non-cirrhotic patients with HCV genotypes 1, 2, 4, 5 and 6, were presented at the conference. The results showed that 98.9% (181/183) of patients treated with JNJ-4178 for 6 weeks achieved SVR12, while 97.8% (178/182) of patients treated with JNJ-4178 for 8 weeks achieved SVR12, with both arms meeting the prespecified endpoint of statistical non-inferiority compared to historic controls. The triple combination was generally well-tolerated in both arms of the study, with the most frequent adverse events being headache and fatigue. Further information on the study can be found at www.clinicaltrials.gov (NCT02765490).

Medivir announced on September 11th 2017 that Janssen Sciences Ireland UC had decided to discontinue the development of JNJ-4178. The discontinuation of development of JNJ-4178 does not affect the ongoing partnership with Janssen on Olysio® (simeprevir), or the existing licensing agreement with Janssen in which simeprevir is included. Medivir continues to be entitled to royalties on sales of single agent simeprevir globally.

For further information, please contact:

Anders Lundin,
Interim CFO Medivir AB,
mobile: +46 (0)73-125-1453

Richard Bethell,
CSO Medivir AB,
mobile +46 (0) 72-704-3211

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.This information was brought to you by Cision http://news.cision.com.

http://news.cision.com/medivir/r/data-on-the-clinical-activity-of-simeprevir-in-combination-with-al-335-and-odalasvir--jnj-4178--pres,c2373044

The following files are available for download:

http://mb.cision.com/Main/652/2373044/739919.pdf

Press release (PDF)

SOURCE Medivir


These press releases may also interest you

at 13:05
Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...

at 12:57
Hinkal Closes Strategic Funding Round to Advance Discreet Trading and Position Liquidation
Hinkal, a multi-chain privacy layer for confidential decentralized finance (DeFi) transactions, today announced a $1.4 million strategic funding round led by SALT Fund, with participation from Draper Associates, SNZ and Peer VC. Additionally, Tal...

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 12:39
Interfuse Adds New Features to its Knowledge Base
In an effort to provide the best service possible, enterprise developer Interfuse, has added several important improvements to its Knowledge Base application. Within this update, new pages accessible in the Knowledge Base include Recently Added,...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:05
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadranttm for Supply Chain Planning Solutions
Kinaxis® Inc. , a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadranttm for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis...

More news about Science and technology...


News published on and distributed by: